title: Sinomenine reduces invasion and migration ability in fibroblast-like synoviocytes cells co-cultured with activated human monocytic THP-1 cells by inhibiting the expression of MMP-2, MMP-9, CD147.
abstract: CD147 expressed by monocytes, macrophages, and synoviocytes cells can stimulate the production of matrix metalloproteinases (MMPs) associated with the development of rheumatoid arthritis (RA). We investigated the effects of Sinomenine (SIN) on invasion and migration ability and gene expression of CD147, MMP-2, MMP-9 of fibroblast-like synoviocytes cells (FLS) co-cultured with activated human monocytic THP-1 cells (A-THP-1) in vitro. SIN is a pure alkaloid extracted from the Chinese medical plant Sinomenium acutum. FLS cells were co-cultured with THP-1 cells which were induced to differentiate into macrophages with phorbol 12-myristate 13-acetate (PMA). Cells were treated with different concentrations of SIN. Invasion and migration ability of cells was tested by transwell assays. Western blot analysis and zymographic analysis were adopted to detect the expression of CD147 and MMPs, respectively. RT-PCR was used to determine the expression of mRNA of CD147, MMP-2, and MMP-9. The invasion and migration ability of the co-cultured cells was significantly inhibited by SIN in a concentration-dependent fashion, and at the same time, the levels of CD147, MMP-2, MMP-9 were markedly down-regulated. This inhibitory effect was most notable at concentrations of 0.25 and 1.00 mM (P < 0.01). Our results point to a possible mechanism of SIN on treatment of RA is the inhibitory effect of SIN on cell invasion and migration ability, which strongly correlates with repressing the expression of CD147, MMP-2, and MMP-9.
authors.affiliation: Laboratory of Immunopharmacology, Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, 100191 Beijing, People's Republic of China. ouyangqiong@gmail.com
authors.forename: Yangqiong
authors.initials: Y
authors.lastname: Ou
authors.forename: Weidong
authors.initials: W
authors.lastname: Li
authors.forename: Xuejun
authors.initials: X
authors.lastname: Li
authors.forename: Zhibin
authors.initials: Z
authors.lastname: Lin
authors.forename: Min
authors.initials: M
authors.lastname: Li
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology*; D051926:Basigin / Q000235:genetics / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D015536:Down-Regulation / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D053505:Matrix Metalloproteinases, Secreted / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009019:Morphinans / Q000494:pharmacology*; D013583:Synovial Membrane / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; C497886:BSG protein, human; D015415:Biomarkers; D061965:Matrix Metalloproteinase Inhibitors; D009019:Morphinans; D051926:Basigin; C009271:sinomenine; D053505:Matrix Metalloproteinases, Secreted; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
references.citation: Rheumatology (Oxford). 2006 Jun;45(6):669-75
references.pmid: 16567358
references.citation: Life Sci. 2006 Jul 10;79(7):665-73
references.pmid: 16566946
references.citation: Life Sci. 2005 Nov 4;77(25):3197-209
references.pmid: 16019035
references.citation: Biochimie. 2005 Mar-Apr;87(3-4):361-8
references.pmid: 15781323
references.citation: Acta Med Okayama. 1976 Feb;30(1):1-20
references.pmid: 61710
references.citation: Biol Pharm Bull. 2009 Sep;32(9):1533-7
references.pmid: 19721228
references.citation: Angiogenesis. 2005;8(1):3-12
references.pmid: 16132613
references.citation: Acta Pharmacol Sin. 2009 Apr;30(4):435-41
references.pmid: 19305422
references.citation: Gene. 1998 Oct 5;220(1-2):99-108
references.pmid: 9767135
references.citation: Cancer Res. 2001 Mar 1;61(5):2276-81
references.pmid: 11280798
references.citation: Yao Xue Xue Bao. 2005 Feb;40(2):127-31
references.pmid: 15875667
references.citation: Environ Toxicol Pharmacol. 2007 Nov;24(3):218-22
references.pmid: 21783814
references.citation: Biol Pharm Bull. 2009 Jan;32(1):116-20
references.pmid: 19122291
references.citation: Biol Pharm Bull. 2009 Sep;32(9):1500-3
references.pmid: 19721222
references.citation: Cancer Res. 1993 Jul 1;53(13):3154-8
references.pmid: 8319225
references.citation: Gene. 2002 Jan 9;282(1-2):75-86
references.pmid: 11814679
references.citation: Cancer Res. 1995 Jan 15;55(2):434-9
references.pmid: 7812975
references.citation: Cancer Lett. 2009 Apr 18;276(2):189-95
references.pmid: 19097686
references.citation: Am J Pathol. 1998 Jan;152(1):199-207
references.pmid: 9422537
references.citation: Int J Immunopharmacol. 1996 Oct;18(10):529-43
references.pmid: 9080247
references.citation: J Biol Chem. 1997 Jan 3;272(1):24-7
references.pmid: 8995219